14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
This is the fourth article in our series on “Closing a Private Equity Transaction.” In Part I, the...
Read More >
Effective March 16, 2020, employers will be able to use a four-factor balancing test in determining ...
Read More >
Representation and warranty insurance has changed the M&A market. The popularity of reps and warrant...
Read More >
On June 18, 2019, Connecticut Governor Ned Lamont signed into law “An Act Combatting Sexual Assault...
Read More >
California is potentially setting the precedent on how “employees” will be defined in the future. ...
Read More >
Synopsis: A recent 4th Circuit decision reiterates the importance of aligning a plan fiduciary’s a...
Read More >